Loading...
XNASMBRX
Market cap5mUSD
Dec 26, Last price  
1.77USD
1D
-2.75%
1Q
-35.64%
Jan 2017
-99.14%
IPO
-99.78%
Name

Moleculin Biotech Inc

Chart & Performance

D1W1MN
XNAS:MBRX chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-14.47%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L+8.61%
-748,360-3,926,361-9,805,000-11,876,000-13,205,000-14,996,000-8,860,000-27,410,000-29,769,000
CFO
-24m
L-12.80%
-423,509-3,764,905-7,324,000-12,203,000-17,198,000-17,771,000-18,951,000-27,639,000-24,101,000
Earnings
Mar 20, 2025

Profile

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
IPO date
Jun 02, 2016
Employees
15
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
29,631
30,862
23,064
Unusual Expense (Income)
NOPBT
(29,631)
(30,862)
(23,064)
NOPBT Margin
Operating Taxes
(1,615)
(7,034)
Tax Rate
NOPAT
(29,631)
(29,247)
(16,030)
Net income
(29,769)
8.61%
(27,410)
209.37%
(8,860)
-40.92%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,166
(23)
74,684
BB yield
-245.66%
0.00%
-2,241.00%
Debt
Debt current
100
116
96
Long-term debt
948
670
222
Deferred revenue
Other long-term liabilities
4,855
77
1,412
Net debt
(22,502)
(42,359)
(70,585)
Cash flow
Cash from operating activities
(24,101)
(27,639)
(18,951)
CAPEX
(124)
(67)
(19)
Cash from investing activities
(124)
(67)
(19)
Cash from financing activities
4,651
(23)
74,724
FCF
(29,749)
(29,480)
(15,790)
Balance
Cash
23,550
43,145
70,903
Long term investments
Excess cash
23,550
43,145
70,903
Stockholders' equity
(131,580)
(101,794)
(72,740)
Invested Capital
163,082
154,513
153,304
ROIC
ROCE
EV
Common stock shares outstanding
1,976
1,907
1,792
Price
0.86
-19.02%
1.06
-43.01%
1.86
-61.11%
Market cap
1,696
-16.10%
2,021
-39.35%
3,333
6.16%
EV
(20,806)
(40,338)
(67,252)
EBITDA
(29,504)
(30,732)
(22,900)
EV/EBITDA
0.71
1.31
2.94
Interest
1,615
Interest/NOPBT